THE EFFECTS OF GABA-B RECEPTOR AGONIST BACLOFEN ON BINGE EATING

GABA-B 受体激动剂巴氯芬对暴饮暴食的影响

• 批准号: 7951344
• 负责人: REBECCA L CORWIN
• 金额: $ 0.05万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951344
• 关键词: Adult; Agonist; Baclofen; Binge Eating; Body Weight decreased; Clinical Research; Cognitive; Computer Retrieval of Information on Scientific Projects Database; Enrollment; Food; Frequencies; Funding; GABA-B Receptor; Grant; Human; Individual; Institution; Link; Measures; Methods; Morbid Obesity; Participant; Pilot Projects; Rattus; Recording of previous events; Research; Research Personnel; Resources; Source; Time; United States National Institutes of Health; Weight; binge type behavior; craving; double-blind placebo controlled trial; success

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Binge eating is defined as consuming more food in a brief period of time than most individuals would consume under similar circumstances, and within the same time period. Binge eating threatens successful, sustained weight loss measures and is linked to weight regain and severe obesity. A number of psychotherapeutic, cognitive, and pharmotherapeutic methods have been used to treat bingeing with moderate success. However, small studies in rats and humans have shown that the GABA-B agonist baclofen can reduce craving and bingeing behavior. Thus, the purpose of this pilot study is to conduct a double-blind, placebo-controlled trial of baclofen as a means to reducing craving and bingeing behaviors in adults with a significant history of bingeing. We hypothesize that the baclofen treatment will significantly reduce craving and the frequency of binge eating. Thirty adults who binge at least 3 times a week will be enrolled in the pilot study. Study involvement will last approximately 18 weeks for each participant.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 暴饮暴食的定义是在短时间内消耗更多的食物，比大多数人在类似情况下消耗的更多，并且在同一时间段内。 暴饮暴食威胁着成功的、持续的减肥措施，并与体重反弹和严重肥胖有关。 许多心理治疗，认知和药物治疗方法已被用于治疗暴饮暴食，并取得了一定的成功。 然而，对大鼠和人类的小型研究表明，GABA-B激动剂巴氯芬可以减少渴望和暴食行为。 因此，本初步研究的目的是进行一项双盲，安慰剂对照试验，巴氯芬作为一种手段，以减少渴望和暴食行为的成年人有显着的历史暴食。 我们假设巴氯芬治疗将显著降低食欲和暴饮暴食的频率。 30名每周至少暴饮暴食3次的成年人将参加这项试点研究。 每例受试者的研究参与将持续约18周。